VIASURE
by certest

"Ready & Easy-to-use" kits.
Lyophilised product

Transport and storage at room temperature.
Shelf-life: 24 months

Validated according to **ISO 13485**
and **CE marked**

Quick SARS-CoV-2

- SARS-CoV-2 virus causes **severe respiratory illness** like those SARS-CoV produced. Although the pneumonia is the principal illness associated, a few patients have developed severe pneumonia, pulmonary edema, acute respiratory distress syndrome, or multiple organ failure and death.

  Centers of Disease Control and Prevention (CDC) believes that symptoms of SARS-CoV-2 may appear in as few as 2 days or as long as 14 days after exposure, being the most common fever, cough, myalgia and dyspnea. Less common symptoms are sore throat, headache, diarrhea and vomiting. It seems that people above 60 years old, males, and people with comorbidities most often have severe disease.

- Diagnosis can be problematic, as a wide range of pathogens can cause acute respiratory infections presenting with similar clinical syndromes. **RT-PCR-based diagnostic confirmation of infected individuals is crucial to contain viral spread because infection can be asymptomatic despite high viral loads.**

- Among the nucleic acid extraction tools, manual or in-house protocols, silica column kits, and automated processes could be found. All of them offer advantages but also have disadvantages, such as handling, sample preparation, the need for equipment and numerous steps to achieve a nucleic acid of optimal quality. **VIASURE Quick *SARS-CoV-2* Detection Kit offers a simple and fast solution for the obtention of viral RNA of the SARS-CoV-2 from respiratory samples (oropharyngeal swabs).** Real-time PCR assays have been shown to be a sensitive and specific diagnostic tool for the detection of SARS-CoV-2.

VIASURE by certest

Quick SARS-CoV-2

VIASURE *Quick SARS-CoV-2* Detection Kit is a product which consists of a sample treatment procedure and a real-time RT-PCR test for a rapid treatment and qualitative detection of RNA from the SARS-CoV-2 in respiratory samples (oropharyngeal/nasopharyngeal swabs and saliva samples), from patients suspected of COVID-19 by their healthcare professional (HCP). This kit is not compatible with transport media containing guanidium thiocyanate or other guanidium salts.

This test is intended for use as an aid for the fast and simple processing of samples for the diagnosis of COVID-19, in combination with clinical and epidemiological risk factors.

RNA is obtained from respiratory specimens. Complementary DNA (cDNA) is synthetised and amplified using real-time RT-PCR and detected using fluorescent reporter dye probes specific for SARS-CoV-2.

Analytical sensitivity

VIASURE *Quick SARS-CoV-2* Detection Kit showed a detection limit of 5 genome copies/rxn, equivalent to 1.2 genome copies/µL, for SARS-CoV-2, on oropharyngeal/nasopharyngeal swabs in VTM and on saliva samples, with a positive rate of ≥95%. (figures 1 y 2).



Figure 1.
Dilution series of SARS-CoV-2 (ORF1ab gene) (10^7-10^1 copies/rxn) template run on the CFX96™ Real-Time PCR Detection System (Bio-Rad) (FAM channel).



Figure 2.
Dilution series of SARS-CoV-2 (N gene) (10^7-10^1 copies/rxn) template run on the CFX96™ Touch Real-Time PCR Detection System (Bio-Rad) (ROX channel).

References - VIASURE *Quick SARS-CoV-2* Real Time PCR Detection Kit

48 determinations VS-ERNCO248TE

For more information and use procedure, read the instructions for use included in this product.

certest

Certest Biotec, S.L. Pol. Industrial Río Gállego II · Calle J, Nº1 50840, San Mateo de Gállego, Zaragoza (Spain)
Tel. (+34) 976 520 354 | viasure@certest.es | **www.certest.es**

VIASURE/ERNCO2-0423EN